DK0433827T3 - Cytotoksisk lumfocytmodningsfaktor - Google Patents
Cytotoksisk lumfocytmodningsfaktorInfo
- Publication number
- DK0433827T3 DK0433827T3 DK90123670T DK90123670T DK0433827T3 DK 0433827 T3 DK0433827 T3 DK 0433827T3 DK 90123670 T DK90123670 T DK 90123670T DK 90123670 T DK90123670 T DK 90123670T DK 0433827 T3 DK0433827 T3 DK 0433827T3
- Authority
- DK
- Denmark
- Prior art keywords
- clmf
- cells
- proteins
- relates
- present
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5434—IL-12
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Transplantation (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US45570889A | 1989-12-22 | 1989-12-22 | |
US52093590A | 1990-05-09 | 1990-05-09 | |
US57228490A | 1990-08-27 | 1990-08-27 |
Publications (1)
Publication Number | Publication Date |
---|---|
DK0433827T3 true DK0433827T3 (da) | 1998-09-28 |
Family
ID=27412641
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK97104656T DK0790255T3 (da) | 1989-12-22 | 1990-12-09 | Monoklonale antistoffer som er rettet mod den cytotoksiske lymfocytmodningsfaktor |
DK97104860T DK0790309T3 (da) | 1989-12-22 | 1990-12-09 | Cytotoksisk 40kD underenhed af lymfocytmodningsfaktor og monoklonale antistoffer rettet derimod |
DK97104682T DK0790308T3 (da) | 1989-12-22 | 1990-12-09 | Cytoksisk lymfocytmodningsfaktor 35kD-underenhed samt monoklonale antistoffer rettet derimod |
DK90123670T DK0433827T3 (da) | 1989-12-22 | 1990-12-09 | Cytotoksisk lumfocytmodningsfaktor |
Family Applications Before (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK97104656T DK0790255T3 (da) | 1989-12-22 | 1990-12-09 | Monoklonale antistoffer som er rettet mod den cytotoksiske lymfocytmodningsfaktor |
DK97104860T DK0790309T3 (da) | 1989-12-22 | 1990-12-09 | Cytotoksisk 40kD underenhed af lymfocytmodningsfaktor og monoklonale antistoffer rettet derimod |
DK97104682T DK0790308T3 (da) | 1989-12-22 | 1990-12-09 | Cytoksisk lymfocytmodningsfaktor 35kD-underenhed samt monoklonale antistoffer rettet derimod |
Country Status (11)
Country | Link |
---|---|
EP (4) | EP0790309B1 (da) |
JP (2) | JP3238418B2 (da) |
AT (4) | ATE369383T1 (da) |
AU (2) | AU6834990A (da) |
BG (1) | BG60933B2 (da) |
CA (3) | CA2572802A1 (da) |
DE (4) | DE69034244T2 (da) |
DK (4) | DK0790255T3 (da) |
HU (1) | HU211879A9 (da) |
IE (1) | IE904694A1 (da) |
NZ (1) | NZ236545A (da) |
Families Citing this family (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5456924A (en) * | 1988-12-23 | 1995-10-10 | Immunotec Research Corporation Ltd. | Method of treatment of HIV-seropositive individuals with dietary whey proteins |
US5811523A (en) | 1988-11-10 | 1998-09-22 | Trinchieri; Giorgio | Antibodies to natural killer stimulatory factor |
US5457038A (en) * | 1988-11-10 | 1995-10-10 | Genetics Institute, Inc. | Natural killer stimulatory factor |
EP0375045A1 (en) * | 1988-12-22 | 1990-06-27 | Duphar International Research B.V | New annelated indole derivatives |
US6683046B1 (en) | 1989-12-22 | 2004-01-27 | Hoffmann-La Roche Inc. | Purification and characterization of cytotoxic lymphocyte maturation factor and monoclonal antibodies thereto |
ZA95960B (en) * | 1994-03-14 | 1995-10-10 | Genetics Inst | Use of interleukin-12 antagonists in the treatment of autoimmune diseases |
US6830751B1 (en) | 1994-03-14 | 2004-12-14 | Genetics Institute, Llc | Use of IL-12 antagonists in the treatment of rheumatoid arthritis |
ES2297831T3 (es) | 1994-05-09 | 2008-05-01 | Oxford Biomedica (Uk) Limited | Vectores retroviricos que presentan una tasa de recombinacion reducida. |
AU695129B2 (en) * | 1995-02-06 | 1998-08-06 | Genetics Institute, Llc | Formulations for IL-12 |
US5891680A (en) * | 1995-02-08 | 1999-04-06 | Whitehead Institute For Biomedical Research | Bioactive fusion proteins comprising the p35 and p40 subunits of IL-12 |
GB9505784D0 (en) * | 1995-03-22 | 1995-05-10 | Lynxvale Ltd | Anti-tumour treatment |
US5853714A (en) * | 1995-03-27 | 1998-12-29 | Genetics Institute, Inc. | Method for purification of IL-12 |
US5880146A (en) * | 1995-06-07 | 1999-03-09 | Fuji Immunopharmaceuticals Corporation | Inhibition of IL-12-induced IFN-γ synthesis by specific bis-phenol compounds as a method of immune modulation |
US5853697A (en) * | 1995-10-25 | 1998-12-29 | The United States Of America, As Represented By The Department Of Health & Human Services | Methods of treating established colitis using antibodies against IL-12 |
GB9609932D0 (en) * | 1996-05-13 | 1996-07-17 | Hoffmann La Roche | Use of IL-12 and IFN alpha for the treatment of infectious diseases |
WO1997046583A1 (fr) | 1996-06-04 | 1997-12-11 | Juridical Foundation The Chemo-Sero-Therapeutic Research Institute | Nouvelle proteine de cytokine feline |
AU4908197A (en) * | 1996-10-18 | 1998-05-15 | Valentis, Inc. | Gene expression and delivery systems and uses |
JP2001503257A (ja) * | 1996-10-18 | 2001-03-13 | バレンティス・インコーポレーテッド | Il―12遺伝子発現および送達系および使用 |
US6054487A (en) * | 1997-03-18 | 2000-04-25 | Basf Aktiengesellschaft | Methods and compositions for modulating responsiveness to corticosteroids |
WO1998041229A1 (en) * | 1997-03-19 | 1998-09-24 | F. Hoffmann-La Roche Ag | USE OF IL-12p40 AS IMMUNOSTIMULANT |
JP2002241398A (ja) * | 1997-06-03 | 2002-08-28 | Chemo Sero Therapeut Res Inst | 新規なイヌサイトカインタンパク質 |
US6060284A (en) | 1997-07-25 | 2000-05-09 | Schering Corporation | DNA encoding interleukin-B30 |
AU763719B2 (en) | 1997-12-08 | 2003-07-31 | Merck Patent Gmbh | Heterodimeric fusion proteins useful for targeted immune therapy and general immune stimulation |
US7026456B1 (en) | 1998-01-23 | 2006-04-11 | Hoffman-La Roche, Inc. | Antibodies against human IL-12 |
SK782002A3 (en) | 1999-07-21 | 2003-08-05 | Lexigen Pharm Corp | FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens |
CA2380331C (en) | 1999-08-09 | 2012-11-20 | Lexigen Pharmaceuticals Corp. | Multiple cytokine-antibody complexes |
AU2005202420B2 (en) * | 1999-09-09 | 2008-08-07 | Merck Sharp & Dohme Corp. | Mammalian cytokines; related reagents and methods |
US7090847B1 (en) | 1999-09-09 | 2006-08-15 | Schering Corporation | Mammalian cytokines; related reagents and methods |
ATE389019T1 (de) * | 1999-09-09 | 2008-03-15 | Schering Corp | Interleukin-12 p40 und interleukin-b30. kombinationen davon. antikörper. verwendungen in pharmazeutische zusammensetzungen |
EP1905832A3 (en) * | 1999-09-09 | 2009-09-09 | Schering Corporation | Mammalian interleukin-12 P40 and interleukin B30, combinations thereof, antibodies, uses in pharmaceutical compositions |
US7115712B1 (en) | 1999-12-02 | 2006-10-03 | Maxygen, Inc. | Cytokine polypeptides |
CA2399832C (en) | 2000-02-11 | 2011-09-20 | Stephen D. Gillies | Enhancing the circulating half-life of antibody-based fusion proteins |
US6902734B2 (en) | 2000-08-07 | 2005-06-07 | Centocor, Inc. | Anti-IL-12 antibodies and compositions thereof |
KR20090010127A (ko) | 2001-03-07 | 2009-01-28 | 메르크 파텐트 게엠베하 | 하이브리드 이소타입 항체 부분구조를 포함하는 단백질을 위한 발현 기술 |
WO2002079415A2 (en) | 2001-03-30 | 2002-10-10 | Lexigen Pharmaceuticals Corp. | Reducing the immunogenicity of fusion proteins |
DE60239454D1 (de) | 2001-05-03 | 2011-04-28 | Merck Patent Gmbh | Rekombinanter, tumorspezifischer antikörper und dessen verwendung |
PT1454138E (pt) | 2001-12-04 | 2012-03-28 | Merck Patent Gmbh | Imunocitoquinas com seletividade modulada |
RU2366664C2 (ru) | 2002-12-17 | 2009-09-10 | Мерк Патент Гмбх | Гуманизированное антитело (н14.18) на основании антитела 14.18 мыши, связывающееся с gd2, и его слияние с il-2 |
EP1702069A2 (en) | 2004-01-05 | 2006-09-20 | EMD Lexigen Research Center Corp. | Interleukin-12 targeted to oncofoetal fibronectin |
EA016022B1 (ru) | 2004-12-21 | 2012-01-30 | Сентокор, Инк. | Выделенное антитело млекопитающего против il-12 и способ изменения его активности |
ES2384055T3 (es) * | 2005-12-30 | 2012-06-28 | Merck Patent Gmbh | Variantes de la interleucina-12p40 con estabilidad mejorada |
WO2009068630A1 (en) | 2007-11-27 | 2009-06-04 | Ablynx N.V. | Immunoglobulin constructs |
US7891807B2 (en) * | 2009-06-11 | 2011-02-22 | Ana Nichole Mansuy | Decorative eyeglass temples |
BR112018069776A2 (pt) | 2016-03-29 | 2019-02-05 | Janssen Biotech Inc | tratamento de psoríase com intervalo de dosagem aumentado de anticorpos anti-il-12 e/ou anti-il-23 |
US10189151B2 (en) | 2016-11-14 | 2019-01-29 | Snap-On Incorporated | Compact head body hammer |
TW201922780A (zh) * | 2017-09-25 | 2019-06-16 | 美商健生生物科技公司 | 以抗il12/il23抗體治療狼瘡之安全且有效之方法 |
JP7421500B2 (ja) | 2018-05-18 | 2024-01-24 | ヤンセン バイオテツク,インコーポレーテツド | 抗il12/il23抗体でループスを治療する安全かつ有効な方法 |
JP7359845B2 (ja) | 2018-09-24 | 2023-10-11 | ヤンセン バイオテツク,インコーポレーテツド | 抗il12/il23抗体で潰瘍性大腸炎を治療する安全かつ有効な方法 |
BR112021023295A2 (pt) | 2019-05-23 | 2022-02-08 | Janssen Biotech Inc | Método de tratamento de doença inflamatória intestinal com uma terapia de combinação de anticorpos para il-23 e tnf-alfa |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5457038A (en) * | 1988-11-10 | 1995-10-10 | Genetics Institute, Inc. | Natural killer stimulatory factor |
CA2002607C (en) * | 1988-11-10 | 2004-01-27 | Gordon G. Wong | Natural killer stimulatory factor |
-
1990
- 1990-12-09 DK DK97104656T patent/DK0790255T3/da active
- 1990-12-09 AT AT97104656T patent/ATE369383T1/de not_active IP Right Cessation
- 1990-12-09 DE DE69034244T patent/DE69034244T2/de not_active Revoked
- 1990-12-09 DK DK97104860T patent/DK0790309T3/da active
- 1990-12-09 EP EP97104860A patent/EP0790309B1/en not_active Revoked
- 1990-12-09 AT AT97104682T patent/ATE366311T1/de not_active IP Right Cessation
- 1990-12-09 DE DE69034247T patent/DE69034247T2/de not_active Revoked
- 1990-12-09 DE DE69034249T patent/DE69034249T2/de not_active Revoked
- 1990-12-09 EP EP97104682A patent/EP0790308B1/en not_active Revoked
- 1990-12-09 EP EP97104656A patent/EP0790255B1/en not_active Revoked
- 1990-12-09 AT AT90123670T patent/ATE163675T1/de not_active IP Right Cessation
- 1990-12-09 DK DK97104682T patent/DK0790308T3/da active
- 1990-12-09 DK DK90123670T patent/DK0433827T3/da active
- 1990-12-09 DE DE69032086T patent/DE69032086T2/de not_active Expired - Lifetime
- 1990-12-09 AT AT97104860T patent/ATE368112T1/de not_active IP Right Cessation
- 1990-12-09 EP EP90123670A patent/EP0433827B1/en not_active Expired - Lifetime
- 1990-12-19 CA CA002572802A patent/CA2572802A1/en not_active Abandoned
- 1990-12-19 CA CA002032653A patent/CA2032653C/en not_active Expired - Lifetime
- 1990-12-19 NZ NZ236545A patent/NZ236545A/xx unknown
- 1990-12-19 CA CA002346997A patent/CA2346997C/en not_active Expired - Lifetime
- 1990-12-20 AU AU68349/90A patent/AU6834990A/en not_active Abandoned
- 1990-12-21 IE IE469490A patent/IE904694A1/en not_active IP Right Cessation
- 1990-12-22 JP JP41325990A patent/JP3238418B2/ja not_active Expired - Lifetime
-
1994
- 1994-01-25 AU AU54712/94A patent/AU674363B2/en not_active Expired
- 1994-03-01 BG BG98632A patent/BG60933B2/bg unknown
-
1995
- 1995-06-20 HU HU95P/P00267P patent/HU211879A9/hu unknown
-
2001
- 2001-08-14 JP JP2001246031A patent/JP3375949B2/ja not_active Expired - Lifetime
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK0433827T3 (da) | Cytotoksisk lumfocytmodningsfaktor | |
DE69332413D1 (de) | Interleukin-2 analoge mit niedriger toxizität zur verwendung in der immuntherapie | |
ATE105869T1 (de) | Formen des koloniestimulierungsfaktors 1. | |
DE69007744D1 (de) | Verwendung von Interleukin 2 zur Behandlung von Leukämien. | |
DK458889A (da) | T-celle vaekstfaktor, fremgangsmaade til fremstilling deraf, farmaceutisk praeparat og detekteringsmetode og kit til brug ved detektering | |
GR3031927T3 (en) | Cysteine depleted il-6 muteins | |
Nishihara et al. | Production of an interleukin-1 inhibitor by cell line P388D1 murine macrophages stimulated with Haemophilus actinomycetemcomitans lipopolysaccharide | |
EP0248583A3 (en) | Treatment of basal cell carcinoma intralesionally with recombinant human alpha interferon | |
Ottmann et al. | Proliferative effects of a recombinant human granulocyte colony-stimulating factor (rg-CSF) on highly enriched hematopoietic progenitor cells | |
Schrader et al. | Molecular classification of T-cell-derived lymphokines | |
BG60657B2 (en) | Human recombinant interleukin-2 muteins | |
ES8703928A1 (es) | Un metodo para preparar la proteina factor de estimulacion de colonias (csf-1)recombinante |